Stoke Therapeutics (STOK) Competitors $11.69 +0.21 (+1.83%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STOK vs. MIRM, XENE, BHC, IBRX, GMTX, ARWR, APLS, TWST, VCEL, and NAMSShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Twist Bioscience (TWST), Vericel (VCEL), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Its Competitors Mirum Pharmaceuticals Xenon Pharmaceuticals Bausch Health Cos ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals Twist Bioscience Vericel NewAmsterdam Pharma Mirum Pharmaceuticals (NASDAQ:MIRM) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Do analysts rate MIRM or STOK? Mirum Pharmaceuticals presently has a consensus target price of $65.50, suggesting a potential upside of 29.78%. Stoke Therapeutics has a consensus target price of $23.20, suggesting a potential upside of 98.46%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has better valuation & earnings, MIRM or STOK? Mirum Pharmaceuticals has higher revenue and earnings than Stoke Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M7.42-$87.94M-$1.61-31.35Stoke Therapeutics$36.56M17.46-$88.98M$0.7914.80 Which has more volatility & risk, MIRM or STOK? Mirum Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Does the media refer more to MIRM or STOK? In the previous week, Stoke Therapeutics had 7 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 14 mentions for Stoke Therapeutics and 7 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat Stoke Therapeutics' score of 0.18 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is MIRM or STOK more profitable? Stoke Therapeutics has a net margin of 26.33% compared to Mirum Pharmaceuticals' net margin of -20.39%. Stoke Therapeutics' return on equity of 19.08% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-20.39% -33.63% -11.50% Stoke Therapeutics 26.33%19.08%15.72% SummaryStoke Therapeutics beats Mirum Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$626.77M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio14.8020.3027.1920.03Price / Sales17.46251.54414.39108.98Price / CashN/A41.7026.2128.59Price / Book2.717.397.925.55Net Income-$88.98M-$55.04M$3.17B$248.49M7 Day Performance3.00%3.01%2.18%5.37%1 Month Performance4.94%-0.21%1.25%6.63%1 Year Performance-10.90%4.48%33.90%21.20% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics3.985 of 5 stars$11.69+1.8%$23.20+98.5%-12.5%$626.77M$36.56M14.80100MIRMMirum Pharmaceuticals3.8528 of 5 stars$50.89-0.4%$65.50+28.7%+45.0%$2.53B$336.89M0.00140Analyst DowngradeXENEXenon Pharmaceuticals2.9188 of 5 stars$31.30-3.4%$54.82+75.1%-5.7%$2.49B$9.43M-9.69210BHCBausch Health Cos3.0314 of 5 stars$6.68+3.4%$7.42+11.0%-3.9%$2.39B$9.63B1.7220,700IBRXImmunityBio2.0736 of 5 stars$2.64-2.2%$12.25+364.0%-57.5%$2.38B$14.74M0.00590News CoverageGap UpGMTXGemini TherapeuticsN/A$54.50+0.7%N/A+17.4%$2.36BN/A-54.5030High Trading VolumeARWRArrowhead Pharmaceuticals3.7448 of 5 stars$15.80-1.7%$43.71+176.7%-34.4%$2.22B$3.55M-11.29400APLSApellis Pharmaceuticals4.4062 of 5 stars$17.31-0.7%$40.05+131.4%-50.4%$2.19B$781.37M0.00770Analyst RevisionTWSTTwist Bioscience4.5244 of 5 stars$36.79+2.4%$50.40+37.0%-21.4%$2.15B$312.97M0.00990News CoveragePositive NewsVCELVericel2.9362 of 5 stars$42.55+2.0%$61.14+43.7%-10.5%$2.10B$237.22M1,418.81300NAMSNewAmsterdam Pharma2.2491 of 5 stars$18.11-2.5%$42.89+136.8%-0.8%$2.08B$45.56M0.004Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies MIRM Alternatives XENE Alternatives BHC Alternatives IBRX Alternatives GMTX Alternatives ARWR Alternatives APLS Alternatives TWST Alternatives VCEL Alternatives NAMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STOK) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts